Semaglutide and Acid Reflux: What GLP-1 Users Need to Know About GERD

*Compounded semaglutide and compounded tirzepatide are not FDA-approved. This article is for educational and informational purposes only and does not constitute medical advice. Clinical data referenced here reflects studies of FDA-approved pharmaceutical compounds unless otherwise noted. Individual results vary. Consult your licensed healthcare provider before starting, stopping, or adjusting any medication. Care at Prescriva is delivered by independently licensed providers, not by Blue Oak Services LLC dba Prescriva, which is a management services organization.*

---

Starting a GLP-1 medication changes a lot about how your body handles food. Your appetite shifts. Your meals get smaller. And for some people, a new or worsening sensation of heartburn or acid reflux arrives in the first few weeks.

If this sounds familiar, you are not alone. Acid reflux is one of the more common concerns that comes up after starting semaglutide, and the answer to "is this normal?" is more nuanced than a simple yes or no.

Here is what the research actually shows about GLP-1 medications and GERD, why the stomach effects work the way they do, and what you can do if heartburn has become part of your experience on this medication.

How Semaglutide Affects Your Stomach

To understand why acid reflux can occur with GLP-1 medications, one key mechanism matters above all others: delayed gastric emptying.

GLP-1 receptor agonists like semaglutide work partly by slowing the rate at which food moves out of your stomach and into the small intestine. This is intentional. When food stays in your stomach longer, fullness signals arrive earlier and last longer. The result is reduced appetite and smaller, more satisfying meals.

Your GI tract is densely populated with GLP-1 receptors. When semaglutide activates those receptors, the vagus nerve signals the stomach to slow down. That is why many people on GLP-1 medications feel full after a modest portion and find that overeating causes significant nausea.

The connection to acid reflux follows from this mechanism. When gastric emptying slows, food and liquid remain in the stomach longer while acid production continues. If that combination creates upward pressure on the lower esophageal sphincter (the valve between your stomach and esophagus), stomach acid can enter the esophagus. That produces the familiar burning sensation people call heartburn or acid reflux.

What the Clinical Evidence Actually Shows

A 2025 review published in *Biomedicines* examined gastrointestinal adverse events associated with GLP-1 receptor agonists and other anti-obesity medications. The authors found that GI adverse events (including nausea, diarrhea, constipation, and gastroesophageal reflux) were reported in 65 to 84 percent of patients treated with liraglutide, semaglutide, or tirzepatide. Nausea and diarrhea were most common. Reflux represented a smaller subset of those GI reports (PMID 41153649).

The same review noted an important pattern: GI effects peak during dose escalation and improve substantially as doses stabilize. The early titration window, when doses are increasing gradually over weeks or months, is when most people notice GI symptoms most acutely.

In the STEP 1 clinical trial of once-weekly semaglutide 2.4mg for obesity, GI adverse events were the most commonly reported adverse events overall. They peaked during titration and declined significantly after participants reached a stable dose (PMID 33567185). The SURMOUNT-1 trial for tirzepatide showed a similar pattern: GI adverse events were most frequent during dose escalation and decreased substantially at stable dosing (PMID 35658024).

The implication is practical. Symptoms you experience in weeks two through eight do not predict your experience at months four or six. The adjustment period is real, but it is time-limited for most people.

A Counterintuitive Research Finding

Here is something that surprises many people, and it is worth understanding.

Despite the mechanism that could theoretically worsen acid reflux, recent research suggests that GLP-1 medications may not actually increase rates of clinically significant GERD.

A 2026 study published in the *Journal of Clinical Gastroenterology* evaluated esophageal function in patients with diabetes who were and were not taking GLP-1 receptor agonists. Semaglutide was the most commonly used GLP-1 medication among those in the study. The researchers found no statistically significant difference in GERD detection rates or esophageal motility patterns between GLP-1 users and non-users. Most GLP-1 users (64 percent) had completely normal esophageal function on formal testing (PMID 42133868).

There is a likely explanation for why this makes sense. Obesity is itself one of the strongest known risk factors for GERD. Excess abdominal weight increases pressure on the stomach, weakens the lower esophageal sphincter, and drives acid upward. As people lose weight on GLP-1 medications, these mechanical pressures decrease. For many patients, improvement in the underlying driver of GERD may offset the temporary effect of delayed gastric emptying.

Weight loss, in other words, may reduce GERD risk over time even while the medication's effect on gastric emptying creates some reflux sensitivity in the short term.

Who Is Most Likely to Notice Acid Reflux

Not everyone experiences heartburn on semaglutide. The people most likely to notice it tend to share common patterns.

Pre-existing GERD. If you had acid reflux before starting semaglutide, the slowed gastric emptying can amplify it, particularly during early titration. Letting your provider know about your history before you begin, or before each dose increase, is useful.

Eating habits that changed with treatment. Some people, relieved by the appetite suppression, still eat close to lying down, eat late in the evening, or do not adjust to smaller portion sizes consistently. These habits interact poorly with slowed gastric emptying and can worsen reflux regardless of the medication.

Rapid dose escalation. The gastric emptying effect is dose-dependent. Moving through titration quickly increases the likelihood of GI symptoms, including reflux. Slower titration, when appropriate, often reduces this.

Carbonated beverages and acidic foods. These can irritate an already sensitive esophagus. Many people find their tolerance for sparkling water and acidic foods decreases on GLP-1 medications, even if they were fine with them before.

Hiatal hernia. This anatomical condition, where the upper part of the stomach pushes through the diaphragm, predisposes people to reflux. Slowed gastric emptying can worsen symptoms in people who have one.

Practical Strategies for Managing Acid Reflux on GLP-1

If you are experiencing heartburn or acid reflux on a GLP-1 medication, several practical adjustments can make a meaningful difference.

Eat smaller meals and eat slowly. Portion size alone is not the only variable. The pace of eating matters too. Eating too quickly overloads the stomach and increases reflux risk. Taking 20 to 30 minutes per meal, even when the meal is small, gives the stomach time to process without excessive pressure.

Stop eating at least two to three hours before lying down. When you recline with a stomach that is still processing food slowly, gravity works against you. This timing window matters more on GLP-1 medications than it did before treatment.

Elevate the head of your bed. A 6 to 8 inch elevation using a foam wedge or bed risers keeps stomach acid from migrating toward the esophagus during sleep. Many people find this simple adjustment reduces nighttime reflux significantly.

Identify and reduce your personal triggers. Semaglutide does not change which foods trigger reflux for you, but it can increase sensitivity to them. Common triggers include coffee, alcohol, citrus, tomato-based foods, chocolate, garlic, onion, and peppermint. Most people identify their personal list within the first month of treatment.

Avoid carbonated beverages. The gas in sparkling water and soft drinks adds pressure to the stomach and worsens reflux. Many GLP-1 users who tolerated carbonation before find it uncomfortable during treatment.

Discuss your titration schedule with your provider. If reflux symptoms are pronounced, your provider may recommend slowing your titration, staying at a lower dose longer before increasing, or adjusting when you take your injection relative to meals. These are standard adjustments in a titration-based program, not signs of treatment failure.

Talk to your provider about over-the-counter options. Antacids, H2 blockers (such as famotidine), and proton pump inhibitors are commonly used to manage reflux. If your symptoms are persistent, your provider may recommend one of these to support you through the titration phase. Do not start any new medication without discussing it with your provider first.

When to Contact Your Provider

Mild heartburn during dose titration is common and typically manageable with the strategies above. Contact your licensed provider sooner if you experience any of the following:

• Acid reflux that does not improve after two to four weeks at a stable dose
• Symptoms severe enough to interfere with sleep or eating
• Difficulty swallowing or a sensation of food being stuck
• Pain that extends to your chest or back
• Significant worsening of pre-existing reflux symptoms
• Persistent vomiting

These may warrant a clinical evaluation, a change in your treatment protocol, or a pause in dose escalation. Your provider can assess whether what you are experiencing is expected titration-related GI effects or something that requires a different approach.

The Long-Term Picture

For most people who experience acid reflux on semaglutide, the pattern follows a predictable arc. Symptoms are most noticeable during dose titration, improve as the dose stabilizes, and often diminish or resolve as weight loss progresses over the first several months.

The 2025 review by Witaszek and colleagues found that structured management of GI adverse events, including early counseling about what to expect, dietary adjustments, and appropriate use of supportive medications, substantially improved adherence and long-term outcomes for people on GLP-1 therapies (PMID 41153649).

The short-term discomfort is real for some people. But the evidence suggests it is, for most, manageable and time-limited.

The Bottom Line

Semaglutide and other GLP-1 medications slow gastric emptying. This creates conditions that can trigger acid reflux in some people, particularly during dose titration and at higher doses. At the same time, research shows that GLP-1 medications do not appear to cause clinically significant changes in esophageal motility or GERD rates overall. The weight loss that GLP-1 medications produce may reduce many of the underlying factors that cause reflux in people with excess weight.

If you are experiencing heartburn, the most effective approach combines practical habits (smaller meals, better timing, avoiding your personal triggers) with an open conversation with your provider about your titration schedule and whether supportive treatment makes sense. For most people, these steps make a real difference.

Ready to explore your options? [Check your eligibility](https://prescriva.com/get-started)

---

*This article is for educational and informational purposes only. Compounded semaglutide and compounded tirzepatide are not FDA-approved. Compounded medications are not reviewed by the FDA for safety, efficacy, or quality. They are not the same as, equivalent to, or interchangeable with FDA-approved products. Individual results vary. All medical decisions at Prescriva are made by independently licensed healthcare providers. Blue Oak Services LLC dba Prescriva is a management services organization and does not practice medicine.*

---

Sources

1. Witaszek T, Biesiada A, Iskra-Trifunovic J, et al. Gastrointestinal Symptoms in Obesity Therapy: Mechanisms, Epidemiology, and Management Strategies. *Biomedicines*. 2025;13(10):2362. PMID: 41153649
2. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. *N Engl J Med*. 2021;384(11):989-1002. PMID: 33567185
3. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. *N Engl J Med*. 2022;387(3):205-216. PMID: 35658024
4. Wang AL, Bach L, Leiman DA. Esophageal Motility Patterns Are Not Impacted By Glucagon-Like Peptide-1 Receptor Agonist Use. *J Clin Gastroenterol*. 2026. PMID: 42133868